• EZ Cap™ Cy5 EGFP mRNA: Assay Design

  2026-08-09

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables a two-axis view of mRNA delivery: Cy5 reports intracellular mRNA-associated fluorescence, while EGFP reports productive translation. This guide translates recent LNP biophysical findings into practical assay design, controls, and interpretation strategies.

• LLC-PK1-MDR1 Model for BBB Permeability Screening

  2026-08-08

  Hu and colleagues developed a Transwell blood-brain barrier surrogate based on LLC-PK1-MOCK/MDR1 cells and combined permeability testing with correction for lysosomal trapping. Across 41 compounds, the model correlated well with unbound brain distribution and provided a practical framework for prioritizing CNS drug candidates before extensive in vivo studies.

• 3X (DYKDDDDK) Peptide for Reliable Cell Assays

  2026-08-07

  This scenario-driven guide explains how 3X (DYKDDDDK) Peptide, SKU A6001, can strengthen upstream protein-validation steps in cell viability, proliferation, and cytotoxicity workflows. It covers epitope exposure, metal sensitivity, handling, interpretation, and practical vendor selection without treating the peptide as a direct viability reagent.

• Epoxomicin in Proteostasis: Precision Tools for ER Stress an

  2026-08-07

  Explore how Epoxomicin, a potent proteasome inhibitor, advances research into protein quality control, ER stress, and disease mechanisms. This article uniquely connects mechanistic insight to real-world assay design, providing actionable guidance for scientists.

• Structure-Based Discovery of SARS-CoV-2 NSP15 Inhibitors

  2026-08-06

  This study employs structure-based virtual screening to identify thymopentin and oleuropein as potent inhibitors of the NSP15 endoribonuclease in SARS-CoV-2. The findings highlight the therapeutic potential of targeting NSP15 to disrupt viral immune evasion, providing a rational framework for future antiviral strategies.

• Tetrahydromagnolol: Unraveling CB2 Agonism in Cancer Metasta

  2026-08-06

  Explore how Tetrahydromagnolol, a potent peripheral CB2 receptor agonist, offers unique mechanistic insights for metastasis and inflammation models. This article provides a deep scientific analysis connecting cannabinoid signaling to cytoskeletal remodeling in cancer.

• MG-132 (Z-LLL-al): Proteasome Inhibition, Redox Balance, and

  2026-08-05

  Explore how MG-132, a potent proteasome inhibitor, enables advanced apoptosis assays and cell cycle arrest studies. This article uniquely bridges redox biology, autophagy modulation, and translational insight for cancer and respiratory research.

• Nicotine’s Role in Chronic Kidney Disease Progression: Mecha

  2026-08-05

  This article synthesizes key findings from Jain and Jaimes (2013), highlighting how nicotine signaling through non-neuronal nAChRs exacerbates chronic kidney disease (CKD) progression in smokers. Mechanistic insights into oxidative stress and pro-fibrotic pathways are discussed, with implications for translational research targeting vascular and fibrotic components of CKD.

• Neuroinflammation in Ischemic Stroke: Mechanisms and Biomark

  2026-08-04

  Xiao et al. (2025) provide a comprehensive synthesis of how inflammation drives both damage and repair after ischemic stroke, highlighting the diagnostic and therapeutic significance of inflammatory biomarkers. Their review integrates diverse evidence streams, including systemic immune activation and traditional Chinese medicine, to guide future research and clinical decision-making.

• Inositol Phosphate Regulation of Sin3L/Rpd3L HDAC via SAP30

  2026-08-04

  This study demonstrates that inositol phosphates up-regulate the deacetylase activity of the Sin3L/Rpd3L HDAC complex through interactions with the SAP30 zinc finger, a mechanism distinct from previously characterized SANT domain-mediated regulation. These findings clarify the evolutionary and mechanistic diversity of chromatin-modifying complex regulation, offering new directions for dissecting multi-subunit protein assembly and activity.

• Rimonabant (SR141716): Selective CB1 Antagonist for Cannabin

  2026-08-03

  Rimonabant (SR141716) is a potent, selective CB1 receptor antagonist widely used in endocannabinoid system and appetite regulation research. Its high CB1 selectivity, reproducible in vitro and in vivo effects, and well-defined solubility make it a benchmark anti-obesity compound for mechanistic studies.

• Antiarrhythmic Drug Effects on KCa2 Channels in AF Research

  2026-08-03

  This study systematically evaluated whether clinically recommended antiarrhythmic agents for atrial fibrillation (AF) target small conductance calcium-activated potassium (KCa2.X) channels, a promising atrial-selective pharmacological target. The findings clarify that, among the drugs tested, only dofetilide and propafenone exhibit measurable inhibition of KCa2.X channels—at concentrations far above therapeutic levels—suggesting current AF therapies do not meaningfully modulate these channels in clinical practice.

• Aloin Isoforms Target SARS-CoV-2 PLpro: Implications for Ora

  2026-08-02

  This study demonstrates that aloin A and B, active ingredients in some oral rinses, selectively inhibit the proteolytic and deubiquitinating activities of the SARS-CoV-2 papain-like protease (PLpro) in vitro, indicating a specific antiviral mechanism. The findings clarify the molecular basis for the antiviral potential of certain oral hygiene agents and provide a framework for evaluating other broad-spectrum antimicrobials in oral infection models.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Technical Guide

  2026-08-01

  The FITC Goat Anti-Mouse IgG (H+L) Antibody addresses the challenge of sensitive and specific detection of mouse IgG in immunoassays that require a reliable, fluorescein-labeled secondary antibody. It is best applied in flow cytometry, immunofluorescence, and fluorescence microscopy workflows using mouse primary antibodies. This reagent should not be used in protocols incompatible with FITC or where cross-reactivity with non-mouse IgG is a concern.

• Selective Autophagy Regulates IRF3 Stability and Immune Bala

  2026-07-31

  This article analyzes how selective autophagy, mediated by CALCOCO2/NDP52 and regulated by the deubiquitinase PSMD14, controls IRF3 protein stability to fine-tune type I interferon responses. The findings reveal a crucial mechanism for balancing antiviral immunity and immune suppression, with implications for transcription factor regulation workflows.

8591 records 9/573 page Previous Next First page 上5页 678910 下5页 Last page